Complete Freund's Adjuvant, 4 mg/mL (5 mL)

Complete Freund's Adjuvant (CFA or FCA) is 4 mg/ml M. Tuberculosis (non-viable) in mineral oil. For in-vivo/in-vitro studies. Typically used for the boost of an immune response. Complete Freund's Aduvant (CFA or...

Reagent

501009

To request a quote or place an order: Click here

For research use only. Not for use in diagnostic procedures.

Complete Freund's Adjuvant (CFA or FCA) is 4 mg/ml M. Tuberculosis (non-viable) in mineral oil. For in-vivo/in-vitro studies. Typically used for the boost of an immune response.

Complete Freund's Aduvant (CFA or FCA) is widely used in immunological research for the preparation of antigen-adjuvant emulsions in laboratory animal studies. CFA contains cell wall components of heat killed Mycobacterium tuberculosis and is often used for the initial injection that stimulates an enhanced immune response.

    References/Citations:

    Malcolm, J., Nyirenda, M. H., Brown, J. L., Adrados-Planell, A., Campbell, L., Butcher, J. P., Glass, D. G., Piela, K., Goodyear, C. S., Wright, A. J., McInnes, I. B., Millington, O. R., & Culshaw, S. (2023). C-terminal citrullinated peptide alters antigen-specific APC:T cell interactions leading to breach of immune tolerance. Journal of autoimmunity, 135, 102994.

    Libánská, A., Randárová, E., Skoroplyas, S., Bartoš, M., Luňáčková, J., Lager, F., Renault, G., Scherman, D., & Etrych, T. (2023). Size-switchable polymer-based nanomedicines in the advanced therapy of rheumatoid arthritis. Journal of controlled release : official journal of the Controlled Release Society, 353, 30–41.

    Hansson, C., Lebrero-Fernández, C., Schön, K., Angeletti, D., & Lycke, N. (2023). Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cells. Mucosal Immunology.

    Lu, C. L., Ortmeier, S., Brudvig, J., Moretti, T., Cain, J., Boyadjiev, S. A., ... & Kim, J. (2022). Collagen has a unique SEC24 preference for efficient export from the endoplasmic reticulum. Traffic, 23(1), 81-93.

    Wang, Y., Pan, P., Khan, A., Çil, Ç., & Pineda, M. A. (2022). Synovial Fibroblast Sialylation Regulates Cell Migration and Activation of Inflammatory Pathways in Arthritogenesis. Frontiers in Immunology, 13.

    Casanova-Vallve, N., Constantin-Teodosiu, D., Filer, A., Hardy, R. S., Greenhaff, P. L., & Chapman, V. (2020). Skeletal muscle dysregulation in rheumatoid arthritis: Metabolic and molecular markers in a rodent model and patients. PloS one, 15(7), e0235702.

    Alvarez, P., Augustín, J. J., Tamayo, E., Iglesias, M., Acinas, O., Mendiguren, M. A., ... & Merino, R. (2020). Therapeutic effects of anti-Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor treatment in psoriasis and arthritis. Arthritis & Rheumatology.

    Poolman, T. M., Gibbs, J., Walker, A. L., Dickson, S., Farrell, L., Hensman, J., ... & Rattray, M. (2019). Rheumatoid arthritis reprograms circadian output pathways. Arthritis Research & Therapy, 21(1), 47.

    Chuang, H. C., Chen, Y. M., Chen, M. H., Hung, W. T., Yang, H. Y., Tseng, Y. H., & Tan, T. H. (2019). AhR–ROR-γt complex is a therapeutic target for MAP4K3/GLKhighIL-17A high subpopulation of systemic lupus erythematosus. The FASEB Journal, 33(10), 11469-11480.

    Mariola Kurowska-Stolarska, Stefano Alivernini, Emma Garcia Melchor, et. al. MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Communications (2017) 8, Article number 15877
    77

    Chris AH Hansel, Lindsay M MacLellan, Rachek S Oldham, et. al. The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens. Immunology and Cell Biology (2014), 1-10

    Campo GM, Avenoso A, D'Ascola A, Nastasi G, et.al. Combined Treatment With Hyaluronan Inhibitor Pep-1 and a Selective Adenosine A2 Receptor Agonist Reduces Inflammation in Experimental Arthritis. Innate Immun. 2013;19(5):462-478

    Eveline Trachsel, Frank Bootz, Michela Silacci, et. al. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Research & Therapy (2007), 9:R9

    Product Insert (PDF) - Informational use only. Please refer to insert included with product.

    Data/Specifications: 

    • Format: Tan liquid with particles.
    • Composition: 4 mg/mL M. Tuberculosis H37 RA (non-viable) in mineral oil.
    • Application: For in-vivo/in-vitro studies. Typically used for the boost of an immune response.
    • Storage: Keep tightly closed. Store at 2-8 °C. Do not freeze.